🔗 Visit the ClinicalTrials.gov page for NCT01075308
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Histone deacetylases in skeletal development and bone mass maintenance. | Gene | 2010 | 1.16 |
| 2 | The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. | Ther Adv Hematol | 2014 | 0.88 |
| 3 | Emerging molecularly targeted therapies in castration refractory prostate cancer. | Prostate Cancer | 2013 | 0.83 |
| 4 | Molecular pathways: targeting ETS gene fusions in cancer. | Clin Cancer Res | 2014 | 0.83 |
| 5 | Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. | Ther Adv Urol | 2015 | 0.78 |
| 6 | A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. | Invest New Drugs | 2015 | 0.77 |
| 7 | Translational and clinical implications of the genetic landscape of prostate cancer. | Nat Rev Clin Oncol | 2016 | 0.76 |
| 8 | Epigenetic modulators as therapeutic targets in prostate cancer. | Clin Epigenetics | 2016 | 0.76 |